Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/26/2022 | $18.00 | Outperform | Wedbush |
| 4/27/2022 | $6.00 | Neutral | Goldman |
| 12/17/2021 | $26.00 | Buy | HC Wainwright & Co. |
| 12/3/2021 | $38.00 | Outperform | Robert W. Baird |
| 12/3/2021 | $38.00 | Outperform | Baird |
| 12/2/2021 | $30.00 | Outperform | Oppenheimer |
| 10/19/2021 | $40.00 | Market Outperform | JMP Securities |
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value. These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company
Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 20
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025$55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update. "We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our cl
4 - Vor Biopharma Inc. (0001817229) (Issuer)
4 - Vor Biopharma Inc. (0001817229) (Issuer)
4 - Vor Biopharma Inc. (0001817229) (Issuer)